Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2006451

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with blood cancers, with immune deficiency from low antibody levels and other disease or treatment factors, are at risk of life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement antibody levels. Government criteria recommend stopping Ig therapy in stable patients, but with no evidence for when or how to do so. RATIONALISE will provide this evidence, to improve patient outcomes, reduce risks and costs, and make better use of blood products for the community.

Funded Activity Details

Start Date: 01-01-2021

End Date: End date not available

Funding Scheme: Clinical Trials and Cohort Studies Grants

Funding Amount: $2,490,421.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

blood transfusion | clinical trial | haematological malignancy | immunoglobulin (ig)

Related Links